@Archisaurus_YMB It seems strange to me that FDA would virtually promise ELI accelerated approval with only data from 100 patients for a year when SAVA is about to release data for 200 patients for a year, expected outstanding efficacy and not one serious adverse event.
@luffdee @Storm4Congress @elonmusk Elon Musk is simply displaying the ethics, standards and principles that made this country great. If you want to live in a socialist country, move to Russia, China, Venezuela, etc. Don't try to force the American people to sacrifice our freedoms to satisfy your woke agenda.
@xavier222222@HeyBooBoo16@SpeakerPelosi And the only people that declared it an insurrection were the leftist Democrats and their supportive mainstream media.
@Archisaurus_YMB@SJ79716665 I understand your frustration. Someone had asked how you could sign up to get news releases about $SAVA and I responded telling them they could sign up for them on the company's website. It was rejected. I'm thinking that some of the "fact checkers" Elon fired ended up on YMB>
@JoeSpringer On page 8 of the newly updated presentation file on the SAVA website investors page, "Data release expected 2nd half January 2023, pending completion of an independent statistical analysis on the clinical dataset."
@JoeSpringer@hobbs1000, chance of being good, as compared to every other therapeutic drug for Alzheimer's disease are a slam dunk. The question is who are you trying to kid.
@Archisaurus_YMB@SJ79716665 Perhaps if you save a post you develop as a simple text file, and if it gets rejected, post it on Twitter. Then I could try to post it on YMB. If rejected, we could assume it's something in the wording. If posted, we'd know it's you they've muted.
@Archisaurus_YMB It should be noted that in 20% of patients treated with Lecanemab, potentially life-threatening reactions to the medication occurred. With over 300,000 doses of Simufilam administered, there have been no serious adverse events.
@Archisaurus_YMB The FDA will likely approve Biogen's next candidate drug, Lecanemab, which seems to be marginally effective in slowing the cognitive decline in Alzheimer's patients. Yet FDA drags their feet in approving Simufilam, which actually reverses the cognitive decline in those treated.
@Archisaurus_YMB It is interesting to note that Biogen's statement regarding this item is that it stands "by the integrity of the actions we have taken." Integrity? Didn't Biogen just pay a huge fine for bribing doctors to prescribe their drugs?
@AngelaBelcamino@elonmusk You don't speak for everyone. What you're saying offends me. If you're offended by someone saying merry Christmas, it's your problem. Stop trying to make it everyone else's problem.
@Daniel76969091 @MrZackMorris Have you done any due diligence on $SAVA? First, they have no revenues. At earnings, they release updated trial results regarding Simufilam, which has always been outstanding. This stock moves on catalysts. The last thing I would want to do is get out before earnings.